FinancialGovernment SolutionsLegalReuters News AgencyRisk Management SolutionsTax & AccountingBlog: Answers OnInnovation @ Thomson Reuters
Directory of sites
Login
Contact
Support
Road to Brexit
Royal Family
The Trump Effect
Detained in Myanmar
Market Analysis
North Korea Revealed
Sport
Lifestyle
Healthcare
January 19, 2018 / 9:32 AM / 3 months ago

BRIEF-Sangui Biotech: Revenues Of $54,000 In H1

Reuters Staff

1 Min Read

Jan 19 (Reuters) - SANGUI BIOTECH INTERNATIONAL INC :

* DGAP-NEWS: SANGUI BIOTECH INTERNATIONAL INC.: - REVENUES OF USD 54,000 IN THE FIRST HALF-YEAR; GRANULOX LICENSE INCOME INCREASED BY 54%.

* REVENUES OF USD 54,000 IN FIRST HALF-YEAR; Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

© 2018 Reuters. All Rights Reserved.